Hennion & Walsh Asset Management Inc. Sells 69,841 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Hennion & Walsh Asset Management Inc. reduced its stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 14.3% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 417,833 shares of the company’s stock after selling 69,841 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Compass Pathways were worth $5,912,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CMPS. EverSource Wealth Advisors LLC boosted its holdings in shares of Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after buying an additional 1,920 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways during the fourth quarter worth $38,000. Parallel Advisors LLC raised its holdings in shares of Compass Pathways by 8,450.6% during the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after acquiring an additional 7,183 shares during the period. Advisory Services Network LLC bought a new stake in Compass Pathways in the 3rd quarter valued at $41,000. Finally, North Star Investment Management Corp. lifted its position in Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after acquiring an additional 7,000 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

Analysts Set New Price Targets

CMPS has been the subject of a number of research reports. TD Cowen reiterated a “buy” rating on shares of Compass Pathways in a report on Monday, June 1st. Wolfe Research restated an “outperform” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. UBS Group set a $18.00 price objective on Compass Pathways in a report on Thursday, May 7th. Oppenheimer reaffirmed an “outperform” rating on shares of Compass Pathways in a research report on Wednesday. Finally, Evercore upgraded Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price on the stock in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Price Performance

CMPS stock opened at $13.54 on Monday. Compass Pathways PLC Sponsored ADR has a 1-year low of $3.97 and a 1-year high of $15.40. The business’s 50 day simple moving average is $12.59 and its 200 day simple moving average is $9.35. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.83 billion, a PE ratio of -2.93 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.25 EPS for the current year.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.